Covetrus Reschedules First Quarter 2019 Earnings Release and Conference Call to May 15 and Files Historical Pro Forma 2018 Financial Information
The rescheduled date will provide the Company, together with its independent accounting firm and transaction legal and financial advisors, with more time to complete and review the financial statement consolidation in order to file the first quarter 2019 10-Q simultaneously with the first quarter 2019 earnings release, which the Company believes is best practice. Importantly, this additional time does not relate to the Company’s business operations or the accounting for those operations but is a reflection solely of the complexities of the transaction and intra-quarter close of the carve-out of the Animal Health Business from
Files 8-K for Historical Pro Forma 2018 Financial Information
Conference Call and Webcast
The 2019 first-quarter conference call is now scheduled to take place on
The conference call can also be accessed by dialing [866-789-2492] for U.S./ Canada participants, or [409-937-8901] for international participants, and referencing confirmation code . A replay of the conference call will be available for two weeks through May , 2019 by dialing [855-859-2056 or 404-537-3406]. The replay confirmation code is .
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,000 employees, serving over 100,000 customers around the globe. For more information about
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our future financial and operating results, plans, objectives, expectations, intentions, and the timing of future announcements of our financial and operating results. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous risks and uncertainties, including but not limited to, risks associated with the ability to successfully integrate operations and employees; the ability to realize anticipated benefits and synergies of the transaction that created Covetrus; the potential impact of the consummation of the transaction on relationships, including with employees, customers and competitors; the ability to retain key personnel; the ability to achieve performance targets; changes in financial markets, interest rates and foreign currency exchange rates, and those additional risks and factors discussed in our Annual Report on Form 10-K filed on March 29, 2019, including those discussed under the heading “Risk Factors.” Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
Nicholas Jansen, Investor Relations firstname.lastname@example.org (207) 550-8106 Kiní Schoop, Public Relations email@example.com (207) 550-8018